



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *Andrew Gersy*
Dated 21 NOV 2000

THIS PAGE BLANK (USPTO)

Patents Form 1/77

Patents Act 1977
(Rule 16)

The
**Patent
Office**

12 APR 2000
NEWPORT

12 APR 00 E528710-1 0008837.7
01/7700 0.00-0008837.7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

12 APR 2000

1. Your reference 100018
2. Patent application number
(The Patent Office will fill in this part) 0008837.7
3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
Global Intellectual Property, Patents
S-151 85
Sodertalje, Sweden

Patents ADP number (if you know it) 7822448001

If the applicant is a corporate body, give the country/state of its incorporation SWEDEN
4. Title of the invention FORMULATION
5. Name of your agent (if you have one) Brown, Andrew Stephen

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited
Global Intellectual Property, Patents
PO BOX 272, Mereside
Alderley Park, Macclesfield
Cheshire, SK10 4GR, GB

Patents ADP number (if you know it) 7822471002
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

15

Claim(s)

2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.
- Signature Lynda M Slack Date 11th April 2000
- Lynda M Slack, Authorised Signatory
12. Name and daytime telephone number of person to contact in the United Kingdom
- 01625 516173

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

FORMULATION

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

5 7α -[9-(4,4,5,5,5-pentafluoropentylsulphonyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphonyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and benzyl benzoate.

10

Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarian function through surgical, radiotherapeutic, or medical means, and, in postmenopausal women, by the use of aromatase inhibitors.

15

An alternative approach to oestrogen withdrawal is to antagonise oestrogens with antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness is often limited by the
20 partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).

The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any of
25 the normal transcriptional hormone responses and consequent manifestations of oestrogens. Such molecules would be "pure" antioestrogens, clearly distinguished from tamoxifen-like ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989,
30 Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.

Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7 α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989).

One of these, 7 α -[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-3,17 β -diol was selected for intensive study on the basis of its pure oestrogen antagonist

5 activity and significantly increased antioestrogenic potency over other available

antioestrogens. *In vitro* findings and early clinical experience with

7 α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol have promoted interest in the development of the drug as a therapeutic agent for oestrogen-dependent indications such as breast cancer and certain benign gynaecological conditions.

10

7 α -[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable salts thereof and any possible solvates of either thereof.

15

Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic

20 activity of tamoxifen.

Because fulvestrant has none of the oestrogen-like stimulatory activity that is characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treatment; and a

25 reduction of tumour invasiveness.

In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also

30 true in humans, these findings could be of extreme importance clinically. Reduced bone

density limits the duration of oestrogen-ablative treatment for endometriosis. Fulvestrant does

not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross the blood-brain barrier.

- 5 European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, which compound is specifically named in Claim 4. It is also
- 10 disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.
- 15 Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/solvent mixture solute since measurements this low could not be achieved in a water only solute).
- 20
- Currently there are a number of sustained release injectable steroidal formulations which have been commercialised. Commonly these are formulations which use oil as a solvent and wherein also additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.

Table 1 - OIL BASED LONG-ACTING INTRAMUSCULAR INJECTIONS

<u>PRODUCT NAME</u>	<u>STEROID</u>	<u>DOSE</u>	<u>TYPE</u>	<u>COMP'</u>	<u>SOURCE</u>	<u>OIL</u>	<u>BzBz</u>	<u>BzO</u> <u>H</u>	<u>EtOH</u>	<u>DOSE</u>	<u>DOSING</u>
SUSTANON 100	Testosterone propionate Testosterone phenylpropionate Testosterone isocaproate Testosterone decanoate	30mg 60mg 60mg 100mg 250mgml ⁻¹	Androgen	Organon	ABPI Data Sheet Comp.1999	Arachis oil		0.1ml		1ml	3 weeks
PROLUTON DEPOT	Hydroxy progesterone hexanoate		Progestogen	Schering HC	ABPI Data Sheet Comp.1999	Castor oil	up to 46%			1 or 2ml	1 week
TOCOGESTAN	Hydroxy progesterone enantate Progesterone α -Tocopherol Estrapronicate Nandrolone undecanoate Hydroxyprogesterone heptanoate	200mg 50mg 250mg 1.3mg 50mg 80mg	Progestogen Mixed	Theramax	Dict. Vidal 1999	Ethyl oleate	*40%			2ml	< 1week
TROPHOBOLINE	Norethisterone heptanoate	200mg	Contraceptive	Schering HC	ABPI Data Sheet Comp.1999	Castor Oil	YES			1ml	8 weeks
BENZO- GYNOESTRYL PROGESTERONE -RETARD GRAVIBINAN	Estradiol hexahydrobenzoate Hydroxy progesterone caproate Estradiol 17- β -valerate Hydroxyprogesterone caproate	5mg 250mgml ⁻¹ 5mg ml ⁻¹ 250mg ml ⁻¹	Estradiol Progestogen Mixed	Roussel Pharlon Schering HC	Dict. Vidal 1998 Dict. Vidal 1999 Dict. Vidal 1995	Arachis Oil Castor Oil Castor Oil	YES YES			1ml 1 or 2ml 1 or 2ml	1 week 1 week 1 - 2 weeks

- 5 -

PARABOLAN	Trenbolone	76mg	Androgen	Negma	Dict. Vidal 1997	Arachis oil	75mg	45mg	1.5ml	2 weeks
DELESTROGEN	Estradiol valerate	20mg/ml 40mg/ml	Estradiol	BMS	J.Pharm. Sci (1964)	Castor Oil	20% 40%	2% 2%		
DELALUTIN	17-Hydroxy progesterone	250mg/ml	Progestrogen	DMS	53(8) 891 J.Pharm. Sci.(1964) 53(8) 891	Castor Oil	YES	up to 2%		

BzBz = benzylbenzoate BzOH = benzylalcohol EtOH = ethanol Dict. Vidal = Dictionnaire Vidal
 5 % are w/v and * are approximate as measured directly from a single sample

In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzybenzoate, benzyl alcohol and ethanol have been used, also volumes of oil needed to solubilise the steroid active ingredient are low. Extended release is achievable for periods from 1 to 8 weeks with the above commercial formulations.

Below in Table 2 is a list showing the solubility of fulvestrant in a number of different solvents.

Table 2 - SOLUBILITY OF FULVESTRANT

SOLVENT	SOLUBILITY (mgml ⁻¹ at 25°C)
Water	0.001
Arachis oil	0.45
Sesame oil	0.58
Castor oil	~20*
Miglyol 810	3.06
Miglyol 812	2.72
Ethyl oleate	1.25
Benzyl benzoate	6.15
Isopropyl myristate	0.80
Span 85 (surfactant)	3.79
Ethanol	>200
Benzyl Alcohol	>200

* castor oil varies according to supplier and also may vary between batches

As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major constituent of the fatty acids within the triglycerides present in castor oil - see (Riffkin et.al. 5 J. Pharm. Sci., (1964), 53, 891).

However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a single injection and achieve a therapeutically significant 10 release rate. To achieve a therapeutically significant release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

15 Currently guidelines recommend that no more than 5mls of liquid is injected intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil fulvestrant would need to be administered in at least 10ml of castor oil, far exceeding the above guidelines, and would have to be administered as two separate injections.

20

The addition of organic solvents in which fulvestrant is freely soluble, and which are miscible with castor oil, may be used, such as an alcohol. With the addition of high concentrations of an alcohol concentrations of $>50\text{mgml}^{-1}$ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of $<5\text{ml}$ - see Table 3 below.

25

It is desired to maintain only the minimum amount of excipients necessary for the performance of the formulation. In Japan injectable formulations containing high concentrations of ethanol may not be approved for sale since a significant number of Japanese are intolerant to ethanol. In addition within Muslim countries high ethanol containing 30 products may not be culturally acceptable. Therefore, there is a need to minimise the amount of alcohols present within such parenteral formulations.

We have surprisingly found that the introduction of benzyl benzoate to the castor oil allows the amount of alcohol needed to solubilise fulvestrant into a concentration of at least 50 mgml⁻¹ to be significantly reduced - see Table 3 below. The finding is surprising since the solubility of fulvestrant in benzylbenzoate - see Table 2 above - is significantly lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower in benzyl benzoate than the solubility of fulvestrant in castor oil.

Therefore, we present as a feature of the invention a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 25% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 10% weight of benzyl benzoate per volume of formulation and a sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

Preferred pharmaceutical formulations of the invention are as described above wherein.

1. The total volume of the formulation is 5ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

2. The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 5ml, or less.

3. The total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5ml.

Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and, preferably, at least 16% w/v. Maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ; 22% w/v or less, 20% w/v or less and 18%w/v or less.

The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceutically-acceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol
5 and benzyl alcohol, preferably the ethanol and benzyl alcohol are present in the formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will
10 be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain some water and possibly other organic solvents, for example alcohol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of ethanol when measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not less than 99.5% ethanol by
15 volume when measured at 15.56°C.

Preferred concentrations of benzyl benzoate present in any of the above formulations are; at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v, at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/v.
20 Maximal concentrations of benzyl benzoate are; 60% w/v or less, 50% w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v.

It will be understood by the skilled person that the benzyl benzoate will be of a quality that it
25 will meet pharmacopoeial standards (such as described in the US, British, European and Japanese pharmacopoeias).

By the use of the term ricinoleate vehicle we mean an oil which has as a majority proportion (at least 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of
30 ricinoleic acid. Conveniently the ricinoleate vehicle is castor oil, ideally of pharmacopoeial standards, as described above.

We have surprisingly found that the above formulations of the invention provide, after intra-muscular injection, satisfactory release of fulvestrant over an extended period of time.

5 This finding is indeed surprising for the following reasons.

1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the injection site as well as a poor release profile. It is believed that the tissue
10 irritation/inflammation was due to the presence of fulvestrant in the form of solid particles. The release profile appeared to be controlled by the extent of inflammation/irritation present at the injection site and therefore difficult to control. Also the fulvestrant release rate was not sufficiently high to be clinically significant.

15 2. Our findings from studies using ^{14}C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of administration.

It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, from
20 the injection site.

It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that the benzyl benzoate is always present
25 at the injection site during the extended release period.

We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and benzyl benzoate, from the formulation vehicle and the site of injection after injection of the formulation, extended release at therapeutically significant levels of
30 fulvestrant over an extended period is still achieved.

By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹ and no more than 8.5 ngml⁻¹ of fulvestrant are achieved in the patient.

- 5 By use of the term "extended release" we mean at least two weeks, at least three weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 32 days \pm 4 days.

Therefore we present as a further feature of the invention an extended release pharmaceutical
10 formulation adapted for intramuscular injection comprising fulvestrant, 25% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 10% weight of benzyl benzoate per volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 50mgml⁻¹ of fulvestrant.

15

By the use of the term "optional pharmaceutically-acceptable excipients" we refer to possible additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant. A preferred optional excipient is a surfactant.

20

As described above fulvestrant is useful in the treatment of oestrogen-dependent indications such as breast cancer and gynaecological conditions, such as endometriosis.

Table 3. shows the solubility of fulvestrant in a castor oil vehicle additionally containing
25 alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor oil.

Table 3

Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 25°C

	% w/v							
Ethanol	5	5	10	10	10	10	15	15
(96%)								
Benzyl	5	5	5	10	10	10	15	15
Alcohol								
Benzyl		15				15		15
Benzoate								
Castor Oil	to 100	to 100	to 100	to 100	to 100	to 100	to 100	to 100
Fulvestrant	27	36	46	54	45	65	76	102
Solubility								
[mgml ⁻¹]								

In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol) is also putatively a compound with the same mode of action as fulvestrant and has a very similar chemical structure. It is believe that the compound will also share with fulvestrant similar physical properties and therefore the current invention will also have application with this compound.

Formulation Example

10 Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filters of 0.2 μ m porosity. The sterile filtrate is kept under a nitrogen overlay as it is filled
15 under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.

20 *See also process flow diagram below*

Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains

25

10% weight per volume of benzyl alcohol

10% weight per volume of ethanol

15% weight per volume of benzyl benzoate

250mg of fulvestrant for each 5ml of finished formulation

30 and the remaining amount as castor oil

FLOW DIAGRAM OF MANUFACTURING**Ingredients/Components**

Fulvestrant
Alcohol
Benzyl Alcohol

Benzyl Benzoate

Castor Oil

Process

STAGE 1: DISSOLUTION OF
ACTIVE AGENT



STAGE 2: MIX



STAGE 3: MAKE TO
WEIGHT



STAGE 4: STERILE FILTRATION
(0.2µm)
INTO BULK RECEIVING VESSEL



STAGE 5: STERILE (0.2µm)
IN-LINE FILTRATION



STAGE 6: ASEPTIC FILLING,
AND STOPPERING



STAGE 7: VISUAL
INSPECTION

References

1. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogens. Steroids 1989; 54:71-99.
- 5 2. Wakeling AE. Novel pure antioestrogens: mode of action and therapeutic prospects. American New York Academy Science 1990a; 595: 348-56.
3. Wakeling AE. Steroidal pure antioestrogens. In Lippman M, Dickson R, editors.
- 10 Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990b: 239-57.
4. Wakeling AE. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. Journal Steroid Biochemistry 1990c; 37: 771-5.
- 15 5. Wakeling AE, Bowler J. Steroidal pure antioestrogens. Journal Endocrinology 1987; 112: R7-10.
6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988; 3: 141-7.

Claims

1. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 25% or less weight of a pharmaceutically-acceptable alcohol per volume of
5 formulation, at least 10% weight of benzyl benzoate per volume of formulation and a sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- 10 2. A pharmaceutical formulation as claimed in claim 1 which contains 22% w/v or less of a pharmaceutically-acceptable alcohol.
3. A pharmaceutical formulation as claimed in claim 1 which contains 20% w/v or less of a pharmaceutically-acceptable alcohol.
- 15 4. A pharmaceutical formulation as claimed in claim 1 which contains and 18%w/v or less of a pharmaceutically-acceptable alcohol.
5. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 60%
20 w/v or less of benzyl benzoate.
6. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 50%w/v or less of benzyl benzoate.
- 25 7. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 45% w/v or less of benzyl benzoate.
8. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 40% w/v or less of benzyl benzoate.
- 30 9. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 35% w/v or less of benzyl benzoate.

10. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 30% w/v or less of benzyl benzoate.

11. A pharmaceutical formulation as claimed in any claim from 1 to 4 which contains 25% w/v or less of benzyl benzoate.

12. A pharmaceutical formulation as claimed in any claim from 1 to 11 wherein the total volume of the formulation is 5ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

10

13. A pharmaceutical formulation as claimed in any claim from 1 to 11 wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 5ml, or less.

14. A pharmaceutical formulation as claimed in claim 13 wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5ml.

15. An extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant, 25% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 10% weight of benzyl benzoate per volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 50mgml⁻¹ of fulvestrant.

100018

Application No: _____

Pillsbury Madison & Sutro

Inventor: J. EVANS *et al*

Filed: 1/9/01

Client & Ref. #: ASTRAZENECA (PAM70635/US)

CL.# 9901 M# 275507